Provides support to ongoing and planned non-clinical programs. Reviews, evaluates, and analyzes and reports data for in vivo and in vitro pharmacology, DMPK and toxicity studies. Understand and identify mechanism of toxicity and pharmacological effects that might produce adverse effects in clinical trials or upon marketing. Work closely with the non-clinical as well as the clinical pharmacology and bio-analytical team members in order to support the activities related to INDs, NDAs as well as early stage compounds. Support regulatory activities related to drafting, review and filing of non-clinical sections of INDs, IBs, annual reports and NDAs.
Education and Related Experience
Otsuka Pharmaceutical Company is a global healthcare company with the corporate philosophy: “Otsuka-people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka Pharmaceutical Company is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 45,000 people worldwide and had consolidated sales of approximately USD 11 billion (€ 9.9 billion) in 2016.
All Otsuka stories start by taking the road less travelled. Learn more about Otsuka Pharmaceutical Company on its global website at www.otsuka.co.jp/en. Learn more about Otsuka in the U.S. at www.otsuka-us.com.